DexCom, Tandem Diabetes fall on Apple glucose monitor new team lead
JHVEPhoto/iStock Editorial via Getty Images

DexCom (NASDAQ:DXCM), Tandem Diabetes Care (NASDAQ:TNDM), and Insulet (NASDAQ:PODD) all closed lower Thursday following a report that Apple (AAPL) has named a new head for its project to develop a glucose monitor that doesn't require a skin prick for a blood sample.


Bloomberg reported that VP of Platform Architecture Tim Millet is now heading the project, known as E5. The plan would be to add blood glucose monitor capability to the Apple Watch.
Millet has been with Apple (AAPL) for 19 years.
DexCom fell 3.5%, Tandem (TNDM) was off 4.3%, and Insulet (PODD) lost 1.3%.


More on DexCom, Tandem Diabetes, Insulet

Why DexCom May Be Up To 40% Undervalued
Tandem Diabetes: Cash Flow And Profitability Trends A Drag On Equity Performance, Reiterate Hold
Insulet: Losing More Weight
Dexcom Denies Weight Loss Drug Threat To CGM Sales - I'd Be A Little Concerned
Insulet: High Growth Not Translating To Economic Value For Shareholders (Rating Downgrade)